This study aims to test the safety and effectiveness of a drug called **Benfotiamine** on people with early Alzheimer's Disease (AD). **Early Alzheimer's Disease** is a brain disorder that affects memory and thinking. The study lasts for 18 months (1.5 years) and involves 406 participants. It's a **double-blind** trial, meaning neither the participants nor the researchers know who gets the actual drug or a placebo (a fake treatment). Benfotiamine will be tested in two doses: 600 mg or 1200 mg per day. The study's first phase (phase 2A) will find the safest dose, and the second phase (phase 2B) will test how well it works over 72 weeks. Participants need to be between the ages of 50 and 89 and have mild memory problems. They also need a study partner who will help them with the study requirements. - **Participation involves regular visits to the clinic over 72 weeks.** - **Participants must not have any major health issues other than early AD.** - **Previous exposure to Benfotiamine or participation in other trials may disqualify you.** This study could help find new ways to slow down memory loss in Alzheimer's patients.